(Sharecast News) - Avacta Therapeutics said on Tuesday that it had agreed two key clinical protocol updates to its faridoxorubicin, or AVA6000, programme, removing the historic cardiac dosing limit and identifying a clear pathway to dose selection ahead of future efficacy studies.
The AIM-traded clinical-stage biopharmaceutical company said regulators and investigators...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE